Additionally, the combination therapy of BIBR1532 and NK cells led to a substantial reduction in Bcl-2 protein expression in both primary AML and Kg-1a cells compared to the monotherapy (Fig. 6B–D). Here, BCL2 is linked to acute myeloid leukemia.